skip to main content

CDI Recurrence Prevention — Medical Practice MCQ

Instant feedback + full explanation. One question, done properly.

Hard"Infectious Diseases"CDI Recurrence Prevention

A patient asks whether bezlotoxumab is routine NHS treatment for a first non-severe episode of Clostridioides difficile infection. What is the best response?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — No; treat according to NICE and seek specialist advice before any non-routine recurrence-prevention therapy

The standard NICE pathway uses an appropriate oral antimicrobial and severity assessment. Bezlotoxumab is not a routine replacement for antibiotics in a first non-severe NHS episode. Specialist recurrence-prevention decisions depend on episode number, timing, comorbidity and local access.

Reference: https://www.nice.org.uk/guidance/ng199